Cargando…
JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342982/ https://www.ncbi.nlm.nih.gov/pubmed/29562474 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.03.016 |
_version_ | 1783555656630927360 |
---|---|
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7342982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73429822020-07-16 JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例 Zhonghua Xue Ye Xue Za Zhi 病例报告 Editorial office of Chinese Journal of Hematology 2018-03 /pmc/articles/PMC7342982/ /pubmed/29562474 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.03.016 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 病例报告 JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例 |
title | JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例 |
title_full | JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例 |
title_fullStr | JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例 |
title_full_unstemmed | JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例 |
title_short | JAK2V617F突变和BCR-ABL融合基因双阳性骨髓增殖性肿瘤二例 |
title_sort | jak2v617f突变和bcr-abl融合基因双阳性骨髓增殖性肿瘤二例 |
topic | 病例报告 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342982/ https://www.ncbi.nlm.nih.gov/pubmed/29562474 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.03.016 |
work_keys_str_mv | AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì AT jak2v617ftūbiànhébcrablrónghéjīyīnshuāngyángxìnggǔsuǐzēngzhíxìngzhǒngliúèrlì |